Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
PharmacoEconomics - United Kingdom
doi 10.1007/s40273-019-00812-6
Full Text
Open PDFAbstract
Available in full text
Date
June 20, 2019
Authors
Publisher
Springer Science and Business Media LLC